Table 1.

Participant demographics and results.

ID	Age	Gender	Injury level	Years post-injury	ASIA	Medications	iTBS site	MEP
1	29	M	C4	5	C	Baclofen	M1 S1	↓ (21.8%) Sham > real
2	39	M	C6–C7	14	C	Baclofen	M1 S1	↑ (4.0%) ↓ (20.3%)
3	26	M	C5	4.5	C	Fesoterodine	M1 S1	↓ (30.8%) ↓ (26.7%)
4	41	M	C6	2	D	Diazepam, pregabalin, cyclobenzaprine	M1 S1	Sham > real ↓ (15.9%)
5	39	M	C5	39	N/A	None	M1 S1	↑ (73.9%) ↓ (25.3%)
6	55	F	C3–C4	2	C	Gabapentin, citalopram	M1 S1	Sham > real ↑ (20.9%)
7	58	M	C6–C7	33	B	Baclofen, clonazepam	M1 S1	↓ (55.0%) ↑ (13.1%)
8	68	M	C4	3	B	Baclofen, pregabalin	M1 S1	↓ (3.9%) ↓ (21.4%)
						Percent of instances demonstrating change (N = 16)		MEP
						↑		25%
						↓		56.25%
						Sham > Real		18.75%

Participant demographic information and individual responses to iTBS are shown.

M, male; F, female; C, cervical spine (i.e., C4); iTBS, intermittent theta burst stimulation; M1, primary motor cortex; S1, primary somatosensory cortex; ASIA, American Spinal Injury Association Impairment Scale (A = no sensory or motor function preserved in sacral segments; B = sensory function is preserved with no motor function; C = sensory function is preserved below the level of injury, most muscles below injury have a grade less than 3; D = motor function is preserved below the level of injury, most muscles below injury have a grade of 3 or more; E = normal sensory and motor function); RMT, resting motor threshold; MEP, motor-evoked potential; ↑, measure is increased following iTBS relative to sham effect (percentage of change exceeding sham effects); ↓, measure is decreased following iTBS relative to sham effect (percentage of change exceeding sham effects); N/A, data could not be obtained.